Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07074886 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
A Phase 2 study of Multiple Sclerosis, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 182
- Enrollment target
- 20
- Study locations
NCT07074886 is a Phase 2 study of Multiple Sclerosis that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 182 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT07074886, a Phase 2 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 182 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.
Conditions Studied
Interventions
- DRUG Ocrelizumab Test Formulation
- DRUG Ocrelizumab Reference Formulation
Study Locations (20)
Other
- IME - Instituto Médico Especializado - Buenos Aires
- Centro de Investigacion en Enfermedades Reumaticas CIER - Ciudad Autonoma Buenos Aires
- Sanatorio del Sur S.A. - San Miguel de Tucumán
- Charite - Universitätsmedizin Berlin - Berlin
Rio Grande do Sul
- Cpn - Centro de Pesquisa Neurologica Porto Alegre Ltda - Porto Alegre
- Núcleo de Pesquisa do Rio Grande do Sul - Porto Alegre
- Instituto do Cerebro do Rio Grande do Sul - Porto Alegre
California
- Profound Research, LLC - Carlsbad
Colorado
- Advanced Neurology of Colorado, LLC - Fort Collins
Florida
- Neurology Associates PA - Maitland
Tennessee
- Hope Neurology - Knoxville
Buenos Aires
- Centro de Especialidades Neurológicas y Rehabilitación - CENyR - CABA
CABA / Buenos Aires
- Focus CECIC - CABA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2025-11-13 |
| Est. Completion | 2030-10-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07074886
The ClinicalTrials.gov registry entry for NCT07074886 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (69% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Ocrelizumab Test Formulation is the first listed.
NCT07074886 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Rio Grande do Sul, California.
Frequently Asked Questions
What is clinical trial NCT07074886 about?
NCT07074886 is a clinical study titled "A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)". The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a co...
What is the current status of trial NCT07074886?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2025-11-13. Estimated completion is 2030-10-30.
What conditions does trial NCT07074886 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT07074886?
The interventions under investigation include: Ocrelizumab Test Formulation (DRUG), Ocrelizumab Reference Formulation (DRUG).
Who is sponsoring clinical trial NCT07074886?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07074886 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Tennessee, Buenos Aires. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
-
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.